This analysis examines the share of new mothers who have significant medical debt (in excess of $250), compared to other young women who did not recently give birth, using data from the Survey of Income and Program Participation (SIPP).
Most patients do not know about the new surprise billing protections and likely also do not know of resources available to seek recourse for incorrect medical bills. This brief provides resources to privately insured patients who receive surprise balan…
Patient-provider email messaging accelerated early in the COVID-19 pandemic as more patients sought medical care remotely, and the addition of billing codes for digital health services and subsequent changes in insurers’ payment policies have enabled p…
People with medical debt are much more likely than those without such debt to show other signs of financial vulnerability, like having no “rainy day” fund, overdrawing a checking account, or relying on costly loans, according to a new KFF analysis of n…
This analysis uses government data to examine the burden of medical debt, including variations based on age, race and ethnicity, and health status . It estimates 9% of adults – or roughly 23 million people -owe medical debt, including 11 million who ow…
This analysis of government data finds that people with medical debt are much more likely to have other forms of financial distress than those without medical debt, like having no “rainy day” fund, overdrawing a checking account, or relying on costly l…
This analysis uses government data to examine the burden of medical debt, including variations based on age, race and ethnicity, and health status . It estimates 9% of adults – or roughly 23 million people -owe medical debt, including 11 million who ow…
Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) …
Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) …
In this column, KFF’s President and CEO Drew Altman explores the nation’s twin health cost crises of affordability, especially for people who are sick and need a lot of health care, and national health spending, and why the solutions often work at cros…